1604610

Risedronate sodium

United States Pharmacopeia (USP) Reference Standard

• 別名: Risedronic acid monosodium salt hemi(pentahydrate)
• 実験式（ヒル表記法）: C₇H₁₀NNaO₇P₂ · 2.5H₂O
• CAS番号: 329003-65-8
• 分子量: 350.13
• MDL番号: MFCD01706268
• UNSPSCコード: 41116107
• NACRES: NA.24

特性

• グレード: pharmaceutical primary standard
• APIファミリー: risedronate
• メーカー／製品名: USP
• アプリケーション: pharmaceutical (small molecule)
• フォーマット: neat
• SMILES記法: OP(C(P(O)([O-])=O)(O)CC1=CC=CN=C1)(O)=O.[Na+]
• InChI: 1S/2C7H11NO7P2.2Na.5H2O/c2*9-7(16(10,11)12,17(13,14)15)4-6-2-1-3-8-5-6;;;;;;;/h2*1-3,5,9H,4H2,(H2,10,11,12)(H2,13,14,15);;;5*1H2/q;;2*+1;;;;;/p-2
• InChI Key: HYFDYHPNTXOPPO-UHFFFAOYSA-L

詳細

詳細

Risedronate sodium is a member of the pyridinyl class of bisphosphonates. It is mostly used as an antiresorptive agent. It can be used in treating and preventing postmenopausal and glucocorticoid-induced osteoporosis.[1]

アプリケーション

Risedronate sodium USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:

• Risedronate Sodium Tablets
• Risedronate Sodium Delayed-Release Tablets

アナリシスノート

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

その他情報

Sales restrictions may apply.

安全性情報

• ピクトグラム: GHS08,GHS07
• シグナルワード: Warning
• 危険有害性情報: H302,H319,H361,H371
• 注意書き: P202 - P260 - P264 - P301 + P312 - P305 + P351 + P338 - P308 + P311
• 危険有害性の分類: Acute Tox. 4 Oral - Eye Irrit. 2 - Repr. 2 - STOT SE 2
• 保管分類コード: 11 - Combustible Solids
• WGK: WGK 3
• 引火点(°F): Not applicable
• 引火点(℃): Not applicable